Novavax Insiders Sold US$593k Of Shares Suggesting Hesitancy
Novavax Insiders Sold US$593k Of Shares Suggesting Hesitancy
Novavax, Inc. (NASDAQ:NVAX) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more.
多位内部人士在过去一年里卖出股份后，诺瓦瓦克斯医药股份股东们可能有理由担心。评估内部人士交易时，了解内部人士是否购买的信息通常比了解他们是否卖出更有益，因为后者可以有多种解读。但是，如果多个内部人士在卖出，股东应该进行更多调查。
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
虽然在长期投资方面内部交易并非最重要的事情，但完全忽略内部交易是愚蠢的。
The Last 12 Months Of Insider Transactions At Novavax
诺瓦瓦克斯医药内部交易的过去12个月
In the last twelve months, the biggest single sale by an insider was when the President of Research & Development, Filip Dubovsky, sold US$384k worth of shares at a price of US$13.90 per share. So what is clear is that an insider saw fit to sell at around the current price of US$13.11. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
在过去的12个月中，研发总裁Filip Dubovsky卖出了价值384,000美元的股票，每股价格为13.9美元，是所有内部人员最大的单笔卖出。因此，明显有内部人士认为出售价格在当前价位13.11美元左右比较合适。虽然内部人士的卖出行为是负面的，但对我们来说，如果股票价格更低时卖出，就更加负面。我们注意到此次交易发生在当前价格附近，因此不太引起关注，但也不算好迹象。
Over the last year we saw more insider selling of Novavax shares, than buying. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在过去的一年中，我们看到更多内部人员卖出诺瓦瓦克斯医药的股票，而不是买入。您可以在下面看到过去12个月内部交易（由公司和个人）的视觉描述。如果您想知道是谁以多少价格和何时卖出，请单击下面的图表！
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
对于那些喜欢发现潜力股票的人，可以免费查看最新内部交易股票的小盘公司名单，这可能正是您要找的机会。
Insiders At Novavax Have Sold Stock Recently
诺瓦瓦克斯医药的内部人员最近出售了股票
There was substantially more insider selling, than buying, of Novavax shares over the last three months. In total, insiders sold US$593k worth of shares in that time. On the flip side, insider Himanshu Shah spent US$34k on purchasing shares (as mentioned above) . The share price has moved a bit recently, but it's hard to argue that the selling is a positive.
过去三个月内，诺瓦瓦克斯医药的内部人士卖出的股票远高于购买，总共在该时间段内卖出了价值593,000美元的股票。另一方面，内部人员Himanshu Shah购买了价值34,000美元的股票（如上所述）。股价最近有些波动，但很难认为卖出是一种积极的信号。
Insider Ownership
内部人员持股情况
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 0.3% of Novavax shares, worth about US$6.8m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.
查看公司内部股权总额可以帮助您了解股东与普通股东是否有很好的对齐。持有高比例股权的内部人员通常会更加关注股东利益。根据我们的数据，内部人员拥有诺瓦瓦克斯医药0.3%的股权，价值约6.8百万美元。虽然比没有强，但我们对这些持股不太满意。
What Might The Insider Transactions At Novavax Tell Us?
诺瓦瓦克斯医药的内部交易可能意味着什么？
The stark truth for Novavax is that there has been more insider selling than insider buying in the last three months. Zooming out, the longer term picture doesn't give us much comfort. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we'd only buy after very careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Novavax. To that end, you should learn about the 4 warning signs we've spotted with Novavax (including 3 which are concerning).
对于诺瓦瓦克斯医药来说，残酷的事实是，在过去的三个月中，内部人员卖出的股票比买入的多。回归长期，情况也不太让我们感到舒适。考虑到大多数公司拥有更高比例的内部持股，我们有些警惕。因此，我们只会在非常谨慎地考虑之后购买。除了了解正在进行的内部交易之外，还要确定诺瓦瓦克斯医药面临的风险。为此，您应该了解我们发现的4个警告信号（包括3个令人担忧的信号）。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然，您可能会在其他地方找到一项出色的投资。因此，请查看此免费的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言，内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者，发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。